Role of bevacizumab therapy in the management of glioblastoma

References

• HegiMEDiserensACGorliaTMGMT gene silencing and benefit from temozolomide in glioblastomaN Engl J Med200535210997100315758010
   PubMed Web of Science ®Google Scholar
• CBTRUSStatistical Report: Primary Brain Tumors in the United States, 2000–2004Central Brain Tumor Registry of the United States2008
   Google Scholar
• BondyMLScheurerMEMalmerBBrain tumor epidemiology: consensus from the Brain Tumor Epidemiology ConsortiumCancer20081137 Suppl1953196818798534
   PubMed Web of Science ®Google Scholar
• NarodSAStillerCLenoirGMAn estimate of the heritable fraction of childhood cancerBr J Cancer19916369939992069856
   PubMed Web of Science ®Google Scholar
• ShibuyaMVascular endothelial growth factor-dependent and -independent regulation of angiogenesisBMB Rep200841427828618452647
   PubMed Web of Science ®Google Scholar
• DvorakHFSioussatTMBrownLFDistribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vesselsJ Exp Med19911745127512781940805
   PubMed Web of Science ®Google Scholar
• ShweikiDItinASofferDKeshetEVascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesisNature199235963988438451279431
   PubMed Web of Science ®Google Scholar
• RenYTsuiHTPoonRTMacrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinomaInt J Cancer20031071222912925952
   PubMed Web of Science ®Google Scholar
• ProescholdtMAHeissJDWalbridgeSVascular endothelial growth factor (VEGF) modulates vascular permeability and inflammation in rat brainJ Neuropathol Exp Neurol199958661362710374752
   PubMed Web of Science ®Google Scholar
• MarchioSPrimoLPaganoMVascular endothelial growth factor-C stimulates the migration and proliferation of Kaposi’s sarcoma cellsJ Biol Chem199927439276172762210488101
   PubMed Web of Science ®Google Scholar
• NagashimaGSuzukiRHokakuHGraphic analysis of microscopic tumor cell infiltration, proliferative potential, and vascular endothelial growth factor expression in an autopsy brain with glioblastomaSurg Neurol199951329229910086494
   PubMedGoogle Scholar
• SandstromMJohanssonMSandstromJBergenheimATHenrikssonRExpression of the proteolytic factors, tPA and uPA, PAI-1 and VEGF during malignant glioma progressionInt J Dev Neurosci1999175–647348110571409
   PubMed Web of Science ®Google Scholar
• NordenADDrappatzJWenPYAntiangiogenic therapies for high-grade gliomaNat Rev Neurol200951161062019826401
   PubMed Web of Science ®Google Scholar
• Lucio-EterovicAKPiaoYde GrootJFMediators of glioblastoma resistance and invasion during antivascular endothelial growth factor therapyClin Cancer Res200915144589459919567589
   PubMed Web of Science ®Google Scholar
• VerhoeffJJvan TellingenOClaesAConcerns about anti-angiogenic treatment in patients with glioblastoma multiformeBMC Cancer2009944420015387
   PubMed Web of Science ®Google Scholar
• CriscuoloGRThe genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factorYale J Biol Med19936642773147516104
   PubMed Web of Science ®Google Scholar
• RisauWMolecular biology of blood-brain barrier ontogenesis and functionActa Neurochir Suppl199460109112
   Google Scholar
• MonacciWTMerrillMJOldfieldEHExpression of vascular permeability factor/vascular endothelial growth factor in normal rat tissuesAm J Physiol19932644 Pt 1C99510028476026
   PubMed Web of Science ®Google Scholar
• ShibuyaMBrain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factorFebs J2009276174636464319664071
   PubMed Web of Science ®Google Scholar
• JiangBHAganiFPassanitiASemenzaGLv-Src induces expression of hypoxia-inducible factor 1 (Hif-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1– involvement of Hif-1 in tumor progressionCancer Res19975723532853359393757
   PubMed Web of Science ®Google Scholar
• GrayMJZhangJEllisLMHIF-1alpha, STAT3, CBP/p300 and Ref-1/APE are components of a transcriptional complex that regulates Src-dependent hypoxia-induced expression of VEGF in pancreatic and prostate carcinomasOncogene200524193110312015735682
   PubMed Web of Science ®Google Scholar
• NiuGWrightKLHuangMConstitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene200221132000200811960372
   PubMed Web of Science ®Google Scholar
• LoHWCaoXZhuHAli-OsmanFConstitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylatorsClin Cancer Res200814196042605418829483
   PubMed Web of Science ®Google Scholar
• MukhopadhyayDTsiokasLZhouXMFosterDBruggeJSSukhatmeVPHypoxic induction of human vascular endothelial growth factor expression through c-Src activationNature199537565325775817540725
   PubMed Web of Science ®Google Scholar
• ClarkeKSmithKGullickWJHarrisALMutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathwayBr J Cancer200184101322132911355942
   PubMed Web of Science ®Google Scholar
• FeldkampMMLauNRakJKerbelRSGuhaANormoxic and hypoxic regulation of vascular endothelial growth Factor (VEGF) by astrocytoma cells is mediated by RasInt J Cancer199981111812410077162
   PubMed Web of Science ®Google Scholar
• ZhangYZhangNDaiBFoxM1B transcriptionally regulates vascular endothelial growth factor expression and promotes the angiogenesis and growth of glioma cellsCancer Res200868218733874218974115
   PubMed Web of Science ®Google Scholar
• NaborsLBGillespieGYHarkinsLKingPHHuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3’ untranslated regions of cytokine and angiogenic factor mRNAsCancer Res20016152154216111280780
   PubMed Web of Science ®Google Scholar
• IdoKNakagawaTSakumaTTakeuchiHSatoKKubotaTExpression of vascular endothelial growth factor-A and mRNA stability factor HuR in human astrocytic tumorsNeuropathology200828660461118498284
   PubMed Web of Science ®Google Scholar
• KerberMReissYWickersheimAFlt-1 signaling in macrophages promotes glioma growth in vivoCancer Res200868187342735118794121
   PubMed Web of Science ®Google Scholar
• McCormackPLKeamSJBevacizumab: a review of its use in metastatic colorectal cancerDrugs200868448750618318567
   PubMed Web of Science ®Google Scholar
• BaoSWuQSathornsumeteeSStem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factorCancer Res200666167843784816912155
   PubMed Web of Science ®Google Scholar
• MathieuVDe NeveNLe MercierMCombining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft modelNeoplasia200810121383139219048117
   PubMed Web of Science ®Google Scholar
• RapisardaAHollingsheadMUranchimegBIncreased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibitionMol Cancer Ther2009871867187719584228
   PubMed Web of Science ®Google Scholar
• Stark-VanceVBevacizumab and CPT-11 in the treatment of relapsed malignant gliomaNeuro Oncol20057369
   Web of Science ®Google Scholar
• VredenburghJJDesjardinsAHerndonJE2ndPhase II trial of bevacizumab and irinotecan in recurrent malignant gliomaClin Cancer Res20071341253125917317837
   PubMed Web of Science ®Google Scholar
• NordenADYoungGSSetayeshKBevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrenceNeurology2008701077978718316689
   PubMed Web of Science ®Google Scholar
• KreislTNKimLMooreKPhase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastomaJ Clin Oncol200927574074519114704
   PubMed Web of Science ®Google Scholar
• LevinVACraftsDCNormanDMHofferPBSpireJPWilsonCBCriteria for evaluating patients undergoing chemotherapy for malignant brain tumorsJ Neurosurg1977473329335894339
   PubMed Web of Science ®Google Scholar
• MacdonaldDRCascinoTLScholdSCJrCairncrossJGResponse criteria for phase II studies of supratentorial malignant gliomaJ Clin Oncol199087127712802358840
   PubMed Web of Science ®Google Scholar
• FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
   PubMed Web of Science ®Google Scholar
• LevinVAChemotherapy of primary brain tumorsNeurol Clin1985348558663001491
   PubMed Web of Science ®Google Scholar
• WilsonCBGutinPBoldreyEBDraftsDLevinVAEnotKJSingle-agent chemotherapy of brain tumors. A five-year reviewArch Neurol19763311739744185991
   PubMedGoogle Scholar
• LevinVAWilsonCBNitrosourea chemotherapy for primary malignant gliomasCancer Treat Rep1976606719724954010
   PubMedGoogle Scholar
• RodriguezLAPradosMSilverPLevinVAReevaluation of procarbazine for the treatment of recurrent malignant central nervous system tumorsCancer19896412242024232555038
   PubMed Web of Science ®Google Scholar
• YungWKAlbrightREOlsonJA phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapseBr J Cancer200083558859310944597
   PubMed Web of Science ®Google Scholar
• YungWKMechtlerLGleasonMJIntravenous carboplatin for recurrent malignant gliomas: a phase II studyJ Clin Oncol1991958601849986
   PubMed Web of Science ®Google Scholar
• BergerMSLeibelSABrunerJMFinlayJLLevinVAPrimary Cerebral TumorsLevinVACancer in the Nervous SystemSecond edNew YorkOxford University Press200275148
   Google Scholar
• NghiemphuPLLiuWLeeYBevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experienceNeurology200972141217122219349600
   PubMed Web of Science ®Google Scholar
• SathornsumeteeSCaoYMarcelloJETumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanJ Clin Oncol200826227127818182667
   PubMed Web of Science ®Google Scholar
• LaiAFilkaEMcGibbonBPhase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerabilityInt J Radiat Oncol Biol Phys20087151372138018355978
   PubMed Web of Science ®Google Scholar
• GutinPHIwamotoFMBealKSafety and efficacy of bevacizumab with hypofractionated stereotactic irradiation for recurrent malignant gliomasInt J Radiat Oncol Biol Phys200975115616319167838
   PubMed Web of Science ®Google Scholar
• NghiemphuPLGreenRMPopeWBLaiACloughesyTFSafety of anticoagulation use and bevacizumab in patients with gliomaNeuro Oncol200810335536018436627
   PubMed Web of Science ®Google Scholar
• IwamotoFMAbreyLEBealKPatterns of relapse and prognosis after bevacizumab failure in recurrent glioblastomaNeurology200973151200120619822869
   PubMed Web of Science ®Google Scholar
• KangTYJinTElinzanoHPeereboomDIrinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safetyJ Neurooncol200889111311818438609
   PubMed Web of Science ®Google Scholar
• ZunigaRMTorcuatorRJainREfficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecanJ Neurooncol200991332933618953493
   PubMed Web of Science ®Google Scholar
• AnanthnarayanSBahngJRoringJTime course of imaging changes of GBM during extended bevacizumab treatmentJ Neurooncol200888333934718389177
   PubMed Web of Science ®Google Scholar
• GonzalezJKumarAJConradCALevinVAEffect of bevacizumab on radiation necrosis of the brainInt J Radiat Oncol Biol Phys200767232332617236958
   PubMed Web of Science ®Google Scholar
• KumarAJLeedsNEFullerGNMalignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of the brain after treatmentRadiology2000217237738411058631
   PubMed Web of Science ®Google Scholar
• TorcuatorRZunigaRMohanYSInitial experience with bevacizumab treatment for biopsy confirmed cerebral radiation necrosisJ Neurooncol2009941636819189055
   PubMed Web of Science ®Google Scholar
• LevinVABidautLHouPRandomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the CNSInt J Radiat Oncol Biol Phys2010 In press.
   Web of Science ®Google Scholar
• HigaGMAbrahamJBiological mechanisms of bevacizumab-associated adverse eventsExpert Rev Anticancer Ther200997999100719589038
   PubMed Web of Science ®Google Scholar